Fortrea Holdings Inc. is a biotechnology company focused on developing and commercializing innovative therapeutics for unmet medical needs, particularly in the fields of oncology and rare diseases. The company leverages advanced scientific research and technology to create transformative treatment options that aim to improve patient outcomes and quality of life. Through a combination of cutting-edge drug development and strategic partnerships, Fortrea Holdings is dedicated to bringing new therapies to market while adhering to rigorous safety and efficacy standards in the healthcare industry. Read More
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential.
However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.
Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE)
fell 4.4% in the afternoon session after the company reported mixed second-quarter financial results, where a massive net loss overshadowed a revenue beat and raised guidance. The contract research organization posted revenues of $710.3 million, which exceeded analysts' expectations. However, investors focused on a staggering GAAP net loss of $374.9 million for the quarter. This loss resulted primarily from a non-cash goodwill impairment charge of $309.1 million. A goodwill impairment is an accounting adjustment made when the value of a company's assets declined. Fortrea attributed this charge to its own falling share price and market-driven interest rate increases. Further concerns arose from a weak book-to-bill ratio of 0.79x, which indicated the company secured less new business than it billed during the period.
Clinical research company Fortrea Holdings (NASDAQ:FTRE) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 7.2% year on year to $710.3 million. The company’s full-year revenue guidance of $2.65 billion at the midpoint came in 5.7% above analysts’ estimates. Its non-GAAP profit of $0.19 per share was significantly above analysts’ consensus estimates.
FORTREA HOLDINGS INC (FTRE) reported strong Q2 2025 earnings, beating revenue and EPS estimates, sparking a 14.6% pre-market surge. Revenue hit $710.3M, exceeding forecasts by 10.6%, while EPS outperformed by nearly 200%. Investors remain bullish despite a GAAP net loss.
DURHAM, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced the appointment of Tracy Krumme as senior vice president, investor relations, succeeding Hima Inguva in this role, who has decided to pursue other career opportunities. Krumme will report to Chief Financial Officer, Jill McConnell, and lead Fortrea’s global investor relations strategy, serving as a key liaison to the investment community.
DURHAM, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it issued grants of employment inducement awards to Anshul Thakral, the Company’s recently appointed President and Chief Executive Officer, as an inducement material to Mr. Thakral becoming a new employee of the Company. The grants were previously approved by the independent members of the Company’s Board of Directors and were made in connection with Mr. Thakral’s start date with the Company on August 4, 2025 (the “Effective Date”).
Let's delve into the US markets on Monday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
NEW YORK - August 1, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Fortrea Holdings Inc. (NASDAQ: FTRE) of a class action securities lawsuit.
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Fortrea Holdings, Inc. (“Fortrea” or the “Company”) (NASDAQ: FTRE) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 25-cv-04630, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fortrea securities between July 3, 2023 and February 28, 2025 both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Fortrea Holdings Inc. (“Fortrea” or the “Company”) (NASDAQ: FTRE) and reminds investors of the August 1, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Bragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Marion Passmore Encourage Investors Who Suffered Losses In Fortrea Holdings (FTRE) To Contact Them To Discuss Their Options
NEW YORK - July 31, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Fortrea Holdings Inc. (NASDAQ: FTRE) of a class action securities lawsuit.
Bragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Marion Passmore Encourage Investors Who Suffered Losses In Fortrea Holdings (FTRE) To Contact Them To Discuss Their Options
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Fortrea To Contact Him Directly To Discuss Their Options
NEW YORK - July 30, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Fortrea Holdings Inc. (NASDAQ: FTRE) of a class action securities lawsuit.
